Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

.

Other Chaperone Programs:

Amicus is accelerating its investment in research and development to assess the potential for using pharmacological chaperones to treat a broader range of human genetic diseases beyond lysosomal storage diseases. As part of this effort, Amicus continues to conduct preclinical studies in Parkinson's disease, funded in part by a grant from the Michael J. Fox Foundation. In addition to the work in Parkinson's, Amicus is investing in new research aimed at evaluating disease targets for other neurodegenerative disorders and metabolic disorders.

Shire Collaboration:

In November 2007, Amicus entered into a strategic collaboration with Shire Human Genetic Therapies (HGT), a business unit of Shire plc, to jointly develop Amicus' three lead pharmacological chaperone compounds for lysosomal storage disorders, Amigal, Plicera and AT2220. In this collaboration valued at up to $440 million including an up front payment and success based clinical and sales milestones and excluding royalties and cost sharing, Shire also reimburses worldwide development costs on a 50/50 basis. Under the agreement, Shire received rights to commercialize these products outside of the United States. Amicus retains all rights to commercialize these products in the United States. Amicus will lead development operations through the end of Phase 2 clinical trials. The companies will then share responsibility for Phase 3 clinical trial development leveraging Shire's significant ex-US regulatory and clinical experience as well as its commercial infrastructure.

Additional Financial Results & Notes

On a reported basis, the net loss attributable to common stockholders for the three months ended March 31, 2008, was $7.7 million as compared to $9.7 million for the same period in 2007. On a non-GAAP basis, the net loss for the three months ended March 31, 2008, was $6.4 million as compared to $8.9 million and the same period in 2007.

Amic
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... July 01, 2015 , ... Apex Therapeutics announced today that company CEO, David ... , The presentation took place on Tuesday, June 16 and provided an ... of APX3330 for the treatment of pancreatic cancer. A copy of the company ...
(Date:6/30/2015)... R-Japan Co.,Ltd. obtained the license of cell processing facility under ... Ministry of Health, Labour and Welfare Kinki Bureau of Health ... fact that R- Japan received the license ... Medical Devices Agency (PMDA) on May 18, 2015 two months ... manufacturing service to medical institutions. As of November 25, 2014, ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... ... is hosting a webinar to provide advanced scientific research into new classes of ... science and energy. Touted as 'the wonder material of the 21st Century' ...
(Date:6/30/2015)... June 30, 2015  Today, Americord Registry, one of the ... Andrew Horne , a partner at Kirkland & Ellis LLP, ... Logo - http://photos.prnewswire.com/prnh/20150630/226958LOGO   "We are ... Board," says Martin Smithmyer , CEO of Americord. "He ... career that will assist Americord,s growth and vision." ...
Breaking Biology Technology:Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2R-Japan Obtained Autologous Stem Cell Manufacturing License from the Ministry of Health, Labour and Welfare 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 3How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 4Americord Registry Announces Andrew Horne as Advisory Board Member 2
... This is the inaugural column of a new ... to feature the experiences and insights provided by the ... approach about the alignment of business process and IT ... change management, business process automation, knowledge management and the ...
... announced Wednesday it will support American Musical Supplys ... supply chain execution solutions. AMS , a ... customer distribution network next year and develop business-to-business ... enterprise vision products. , ,AMS was driven ...
... cheers and high-fives in Janesville last week as General Motors ... GM assembly line, a decision that will keep high-wage manufacturing ... invest $175 million in the Janesville line means the plant ... company wont say whether the plants total of 3,900 jobs ...
Cached Biology Technology:GM Choice is Great News, But Wisconsins Economy Must Keep on Truckin to Prosper in a New Era 2
(Date:6/23/2015)... GARDENS, Fla. , June 23, 2015 ... identity management and authentication solutions, today announced enhanced ... strong, multi-factor authentication solution.  The enhancements build ... use of the DigitalPersona Altus platform and ... reader compatibility. In today,s environment ...
(Date:6/17/2015)... June 17, 2015  Synaptics Inc. (NASDAQ: ... today announced that Xiaomi, one of the world,s ... ClearPad ® family of capacitive touchscreen ... circuits (DDICs) for its latest smartphones, the Xiaomi ... for full in-cell display solutions and DDICs in ...
(Date:6/16/2015)... Fingerprint Cards (FPC) raises the revenue ... amount to at least 340 MSEK to that it will ... in market growth and orders received the revenue guidance for ... for 2015 will exceed 1,500 MSEK to an updated guidance ... Due to receipt of orders of touch fingerprint ...
Breaking Biology News(10 mins):Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 3Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3
... conservation biologists to worry about species extinction, Yale biologists are ... that force their extinction, according to a report in Ecology ... not only survive, but also reproduce. Paul Turner , ... Yale, tested the practicality of luring a virus population into ...
... study in Switzerland uses the tools of physics to ... time in the noisy cellular environment. , In ... Systems Biology, researchers from the Ecole Polytechnique Federale de ... on specific biochemical processes, reflecting recent association studies in ...
... labeled a “night owl?report more pathological symptoms related to ... their nocturnal sleeplessness by extending their time in bed ... according to a study published in the April 15th ... , The study, authored by Jason C. Ong, PhD, ...
Cached Biology News:Yale biologists 'trick' viruses into extinction 2Keeping the body in sync -- The stability of cellular clocks 2'Night owls' report more insomnia-related symptoms 2
SAPK/JNK Antibody...
Mouse monoclonal [DJR3] to DcR1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 8794 SwissProtID: O14798...
Tris-EDTA Buffer Solution, 1X, pH 8.0, sterile, Molecular Biology Grade...
Component in MasterPure™ Purification Kits...
Biology Products: